- The Phase 3 ICONIC-TOTAL study evaluated icotrokinra over 52 weeks.
- 72% of scalp psoriasis patients achieved ss-IGA 0/1, 57% achieved ss-IGA 0.
- 85% of genital psoriasis patients achieved sPGA-G 0/1, 73% achieved sPGA-G 0.
- Adverse event rates were similar through Week 52 with no new safety signals.
Study Overview
The Phase 3 ICONIC-TOTAL study evaluated icotrokinra, a targeted oral peptide, over 52 weeks in adults and adolescents with plaque psoriasis affecting high-impact sites like the scalp, genitals, and hands/feet.
Key Findings
In patients with scalp psoriasis, 72% achieved a scalp-specific Investigator’s Global Assessment (ss-IGA) score of 0/1, and 57% achieved ss-IGA 0. For genital psoriasis, 85% reached a Physician’s Global Assessment of Genitalia (sPGA-G) score of 0/1, with 73% achieving sPGA-G 0.
Hand/Foot Psoriasis Results
In a smaller subset with hand/foot psoriasis, icotrokinra showed increased skin clearance from 42% at Week 16 to 62% at Week 52, achieving a hand and/or foot Physician’s Global Assessment (hf-PGA) score of 0/1.
Overall Efficacy and Safety
Overall, 67% of patients treated with icotrokinra achieved clear or almost clear skin (IGA 0/1), and 44% achieved completely clear skin (IGA 0) at Week 52. Adverse event rates were similar through Week 52, with no new safety signals identified.
